

Innovations in treatment-resistant depression (TRD): evolution to rapid, durable, low-burden therapies

TRD remains one of psychiatry's most urgent challenges, with many patients inadequately responding to multiple lines of therapy.

This industry session presents clinical evidence on intranasal mebufotenin (5-MeO-DMT), a rapid-acting neuroplastogen designed to deliver durable symptom relief without the burden of daily dosing or extended monitoring.

Topics:



Unmet needs in TRD and the scientific rationale for new approaches



Intranasal mebufotenin (5-MeO-DMT), a rapid-acting neuroplastogen: efficacy, durability, and safety findings



From trial to practice: considerations for scalable clinical adoption

- **Sunday 11th October 2026**
- **17:45 - 18:30 CEST**
- **Room 14c**
- **Session ID: IMS06, Industry Mini Session**

Speakers:



Prof. Gerhard Gründer
Professor of Psychiatry and
Head of the Department of
Molecular Neuroimaging
*Central Institute of Mental
Health in Mannheim*



Dr. Sandhya Prashad
Medical Director *Houston
Ketamine Therapeutics
and Houston Center for
Advanced Psychiatric
Treatment*



Dr. Mathieu Seynaeve
Senior Medical Director,
Clinical Development
AtaiBeckley